Payment overview · 2025
General Payments
$1,216.91
59 reported records · 18 companies
Healthcare provider profile · identity verified
Alakananda Chakrabarty, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COAL TOWNSHIP, PA · NPI 1205808151
Verified facts
What the public records show
CMS Open Payments records show Alakananda Chakrabarty, MD received $1,216.91 in general payments during 2025 across 59 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 855 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $299.28 | 24.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.15 | 8.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $107.35 | 8.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.60 | 8.8% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.34 | 8.1% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $60.38 | 5.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.87 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.65 | 4.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.43 | 3.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.79 | 3.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.47 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.57 | 3.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.73 | 3.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.59 | 2.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.39 | 2.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.12 | 2.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.21 | 1.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $15.99 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,216.91 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $213.55 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $192.93 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $187.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $167.56 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $90.12 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.12 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.12 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.12 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $60.38 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.79 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 855 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 192 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 266 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
192 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 38 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
855 | 92 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2227 | 335 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1673 | 217 |
| Amlodipine Besylate | Amlodipine Besylate | 1122 | 126 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1074 | 99 |
| Furosemide | Furosemide | 1041 | 140 |
| Potassium Chloride | Potassium Chloride | 966 | 92 |
| Omeprazole | Omeprazole | 939 | 200 |
| Metoprolol Succinate | Metoprolol Succinate | 883 | 139 |
| Eliquis | Apixaban | 855 | 92 |
| Lisinopril | Lisinopril | 826 | 143 |
| Gabapentin | Gabapentin | 779 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 648 | 89 |
| Warfarin Sodium | Warfarin Sodium | 638 | 38 |
| Mirtazapine | Mirtazapine | 602 | 45 |
| Metformin Hcl | Metformin Hcl | 546 | 98 |
| Prednisone | Prednisone | 543 | 210 |
| Simvastatin | Simvastatin | 525 | 70 |
| Donepezil Hcl | Donepezil Hcl | 517 | 36 |
| Sertraline Hcl | Sertraline Hcl | 478 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 456 | 56 |
| Lorazepam | Lorazepam | 454 | 87 |
| Losartan Potassium | Losartan Potassium | 441 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 434 | 68 |
| Torsemide | Torsemide | 412 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 389 | 52 |
| Famotidine | Famotidine | 356 | 42 |
| Tramadol Hcl | Tramadol Hcl | 350 | 55 |
| Trazodone Hcl | Trazodone Hcl | 306 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 299 | 38 |
| Pregabalin | Pregabalin | 281 | 40 |
| Allopurinol | Allopurinol | 273 | 43 |
| Montelukast Sodium | Montelukast Sodium | 271 | 41 |
| Jardiance | Empagliflozin | 266 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 244 | 18 |
| Ezetimibe | Ezetimibe | 235 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 233 | 20 |
| Levetiracetam | Levetiracetam | 230 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 218 | 35 |
| Januvia | Sitagliptin Phosphate | 214 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 201 | 27 |
| Carvedilol | Carvedilol | 198 | 25 |
| Divalproex Sodium | Divalproex Sodium | 192 | 12 |
| Farxiga | Dapagliflozin Propanediol | 192 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 36 |
| Olanzapine | Olanzapine | 184 | 12 |
| Alprazolam | Alprazolam | 181 | 23 |
| Finasteride | Finasteride | 178 | 11 |
| Metformin Hcl Er | Metformin Hcl | 172 | 33 |
| Clonazepam | Clonazepam | 170 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 57 |
| Meloxicam | Meloxicam | 151 | 25 |
| Alendronate Sodium | Alendronate Sodium | 150 | 35 |
| Spironolactone | Spironolactone | 150 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 148 | 22 |
| Ozempic | Semaglutide | 143 | 23 |
| Baclofen | Baclofen | 141 | 35 |
| Buspirone Hcl | Buspirone Hcl | 141 | 23 |
| Risedronate Sodium | Risedronate Sodium | 140 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 15 |
| Myrbetriq | Mirabegron | 135 | 18 |
| Atenolol | Atenolol | 132 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 120 | 49 |
| Aripiprazole | Aripiprazole | 114 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 114 | 67 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 112 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 111 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 20 |
| Ibuprofen | Ibuprofen | 106 | 18 |
| Bupropion Xl | Bupropion Hcl | 104 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 103 | 18 |
| Celecoxib | Celecoxib | 102 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 15 |
| Bethanechol Chloride | Bethanechol Chloride | 94 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 18 |
| Tradjenta | Linagliptin | 94 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 20 |
| Colestipol Hcl | Colestipol Hcl | 85 | suppressed |
| Carbamazepine | Carbamazepine | 81 | suppressed |
| Nystatin | Nystatin | 81 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 24 |
| Lactulose | Lactulose | 80 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 80 | suppressed |
| Risperidone | Risperidone | 80 | suppressed |
| Bumetanide | Bumetanide | 78 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 75 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 40 |
| Glipizide Er | Glipizide | 74 | 15 |
| Latanoprost | Latanoprost | 74 | 11 |
| Colchicine | Colchicine | 73 | 15 |
| Memantine Hcl | Memantine Hcl | 73 | 12 |
| Amoxicillin | Amoxicillin | 72 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 51 |
| Glipizide | Glipizide | 72 | 11 |
| Irbesartan | Irbesartan | 71 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 70 | 16 |
| Terazosin Hcl | Terazosin Hcl | 70 | suppressed |
| Fluconazole | Fluconazole | 69 | 25 |
| Lamotrigine | Lamotrigine | 68 | suppressed |
| Metolazone | Metolazone | 67 | suppressed |
| Linzess | Linaclotide | 66 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 62 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 30 |
| Incruse Ellipta | Umeclidinium Bromide | 61 | suppressed |
| Glimepiride | Glimepiride | 59 | suppressed |
| Cephalexin | Cephalexin | 58 | 38 |
| Ibandronate Sodium | Ibandronate Sodium | 58 | 11 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 56 | suppressed |
| Lacosamide | Lacosamide | 55 | suppressed |
| Gemfibrozil | Gemfibrozil | 54 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 53 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 52 | suppressed |
| Fenofibrate | Fenofibrate | 52 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 50 | suppressed |
| Rybelsus | Semaglutide | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 28 |
| Meclizine Hcl | Meclizine Hcl | 49 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 15 |
| Novolog Flexpen | Insulin Aspart | 48 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 48 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 11 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 38 |
| Spiriva Handihaler | Tiotropium Bromide | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 14 |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Fentanyl | Fentanyl | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Timolol Maleate | Timolol Maleate | 35 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Prolia | Denosumab | 33 | 21 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 23 |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 20 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Jantoven | Warfarin Sodium | 27 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Estradiol | Estradiol | 26 | 12 |
| Jentadueto | Linagliptin/Metformin Hcl | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Erythromycin | Erythromycin Base | 23 | 14 |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 13 |
| Primidone | Primidone | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 14 |
| Clotrimazole | Clotrimazole | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 18 |
| Phenytoin | Phenytoin | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Ofloxacin | Ofloxacin | 18 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Niacin Er | Niacin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | 14 |
| Novolog | Insulin Aspart | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,216.91 · 59 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, JARDIANCE, KISUNLA, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, PREVNAR 20, QULIPTA, Qelbree, REPATHA, REXULTI, SPRAVATO, UBRELVY, Wegovy, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error